Adiponectin is a hormone secreted by fat cells that improves insulin sensitivity and reduces inflammation, unusual for a hormone produced by adipose tissue. Unlike leptin, adiponectin levels inversely correlate with body fat: more fat tissue typically means less adiponectin.
Higher adiponectin reflects better metabolic health, improved insulin sensitivity, and lower cardiovascular risk. It's protective against type 2 diabetes, atherosclerosis, and some cancers. The ratio of leptin to adiponectin (L/A ratio) is an emerging marker of metabolic dysfunction that captures both the dysregulated satiety signaling and the loss of adiponectin's protective effects in one comparison.
Optimal Adiponectin: 18-37 µg/mL.
Typically re-tested every 12 weeks.
Unlike most hormones made by fat tissue, adiponectin moves in the opposite direction to fat mass. As visceral fat accumulates, circulating adiponectin tends to fall, which is why it is studied as an early metabolic signal rather than a late one. It is an optimization marker, not a stand-alone diagnostic test.
Adiponectin is a protein hormone released almost entirely by fat cells that makes muscle and liver tissue more responsive to insulin and helps quiet low-grade inflammation.
It does not circulate as a single uniform molecule. Adiponectin assembles into low-molecular-weight trimers, medium-weight hexamers and high-molecular-weight multimers, and these isoforms behave differently in the body, with the high-molecular-weight form generally regarded as the most metabolically active fraction 1. A standard lab test usually reports total adiponectin, while some settings report the high-molecular-weight fraction separately, so two results are not always measuring the same thing.
The hormone acts through adiponectin receptors on muscle, liver and other tissues. Downstream, it is thought to activate energy-sensing pathways that increase fatty acid oxidation in muscle and reduce glucose output from the liver. The practical consequence is that, for a given amount of insulin, tissues take up glucose more readily. Adiponectin also interacts with inflammatory signalling in blood vessel walls and fat tissue.
Production is influenced by the ADIPOQ gene, and variation in that gene has been examined in relation to both blood glucose regulation and coronary artery disease 2. That genetic component matters for interpretation. Two people with identical body composition and identical diets can carry meaningfully different baseline adiponectin values, which is one reason a single number is read as part of a pattern rather than as a verdict.
It matters because it sits upstream of several things clinicians already track, including insulin sensitivity, triglycerides, HDL cholesterol and vascular inflammation, and it often shifts before those downstream markers do.
In people carrying excess fat mass, the picture is more complicated than low production alone. Research describes a state sometimes called adiponectin resistance, in which tissue responsiveness to the hormone appears blunted even when circulating amounts are not dramatically reduced 3. Later work has examined how adiponectin, leptin and insulin signalling interact in that resistant state, suggesting the three hormones are best read together rather than in isolation 4.
The marker also appears across conditions that are not purely metabolic. In polycystic ovary syndrome, research suggests high-molecular-weight adiponectin is inversely associated with sympathetic nervous system activity 5. In psoriasis, a meta-analysis of published studies reported differences in adiponectin levels compared with controls, consistent with the hormone's links to systemic inflammation 6. Neither finding makes adiponectin a test for those conditions. They illustrate that the hormone sits at the intersection of fat tissue, inflammation and metabolic control.
For someone focused on long-term health rather than on a diagnosis, that is the useful framing. Adiponectin is a window into how fat tissue is behaving, not just how much of it there is. Two people at the same weight can have very different adiponectin values, and the difference tends to track with where fat is stored and how metabolically active it is.
Most laboratories report total adiponectin in micrograms per millilitre, with a wide reference interval that differs by sex. Women generally run higher than men at the same body composition.
| Group | Typical lab reference range | FitScript optimal range |
|---|---|---|
| All adults | 5 to 50 µg/mL | 18 to 37 µg/mL |
| Men | 4 to 40 µg/mL | 12 to 26 µg/mL |
| Women | 5 to 50 µg/mL | 18 to 37 µg/mL |
Reference ranges vary by lab, age and sex, and adiponectin assays are not standardised across platforms, so compare results from the same laboratory and the same method where possible. The optimal ranges shown are FitScript's optimization targets, not diagnostic cut-offs, and a value outside them is not a diagnosis of anything.
There is no age-banded range supplied here, and inventing one would be worse than leaving it out. What is reasonable to say is that adiponectin tends to differ across life stages and that interpretation in children, in pregnancy and in older adults follows different logic than it does in a healthy adult of working age.
Because the reference interval is so wide, the single most useful thing you can do with adiponectin is measure it more than once. A value of 14 µg/mL means something quite different if last year's reading was 9 than if it was 22, even though both sit inside the standard range.
A high result most often reflects low fat mass, female sex, older age, or a medication or clinical state that raises the hormone, and on its own it is not a symptom-producing finding.
What people notice. Adiponectin has no symptom signature. Nobody feels a high adiponectin level. It is picked up on a panel, and whatever symptoms are present usually belong to the underlying situation rather than to the hormone itself.
Common contributors. Leanness and a low proportion of visceral fat are the most ordinary explanations. Sustained fat loss and sustained calorie restriction are associated with rising adiponectin. Some medicines that improve insulin sensitivity raise it as well. In an early clinical proof-of-concept study of a prototype insulin sensitizer, changes in adiponectin were among the measured responses 7. Reduced clearance also matters, since the hormone is cleared in part by the kidneys, and advanced kidney disease, heart failure and type 1 diabetes are all clinical settings in which adiponectin is often reported as elevated. A licensed provider is the right person to sort out which of these applies to a given person.
Longer-term interpretation. This is where the marker stops being a simple more-is-better number. In some older and sicker populations, high adiponectin can sit alongside worse outcomes, a pattern often discussed as the adiponectin paradox. The picture is not uniform. One study in community-dwelling older adults found adiponectin was not associated with decline in kidney function over the follow-up period 9. Separately, adiponectin has been examined alongside other inflammatory and metabolic markers in relation to liver and biliary tract cancer risk in a large cohort analysis 8. These are associations; they do not establish that the hormone causes harm.
A markedly high result in someone who is not lean is the kind of finding worth discussing with a clinician promptly, alongside kidney function, cardiac markers and a full clinical history.
A low result is most commonly associated with higher visceral fat and reduced insulin sensitivity, and it frequently appears alongside a cluster of other suboptimal metabolic markers rather than on its own.
What people notice. Again, nothing directly. What people tend to report in this metabolic pattern is post-meal fatigue, difficulty losing weight around the midsection, rising blood pressure or creeping fasting glucose. Those are features of the broader picture, not of the hormone, and none of them confirms a low adiponectin level.
Common contributors. Accumulated visceral and liver fat is the dominant one. Physical inactivity, short or fragmented sleep, smoking, and dietary patterns heavy in refined carbohydrate and alcohol are all associated with lower values. Chronic inflammatory conditions appear in this group too, which is consistent with the meta-analytic findings reported in psoriasis 6. Genetics contributes as well, through ADIPOQ variation 2.
Longer-term interpretation. Low adiponectin is consistently associated in the research literature with insulin resistance and with the cluster of findings described as metabolic syndrome, and it has been studied as a link between disordered glucose handling and coronary artery disease 2. The interaction with leptin and insulin signalling is part of why a low reading is rarely an isolated problem 4. It is also why interventions aimed at visceral fat, rather than at adiponectin directly, are the ones that tend to move the number.
The useful next step after a low result is not to chase the hormone. It is to look at fasting insulin, glucose, A1C and triglyceride to HDL ratio with a clinician, and decide from the pattern.
Several things shift adiponectin, and some of them have nothing to do with your metabolic health, so testing conditions deserve as much attention as the number itself.
Testing conditions. Assay type is the big one. Total adiponectin and high-molecular-weight adiponectin are different measurements, and the isoform distribution carries its own biological meaning 1. Laboratories also use different methods with different calibration, so results do not transfer cleanly between labs. Sample handling and storage can affect the reading. Most testing is done fasting, in the morning, for consistency rather than because food dramatically alters the result.
Medications and clinical states. Insulin-sensitizing medicines have been observed to raise adiponectin in clinical research 7. Thyroid status interacts with insulin sensitivity, and one study reported an association between thyrotropin levels and insulin sensitivity even within the euthyroid range in adolescents with obesity 10. Kidney function affects clearance. Any prescription medicine that influences insulin sensitivity, hormones or inflammation can shift the result, and only a licensed provider who has reviewed your full medication list can judge what is contributing. No dosing guidance belongs in a page like this one, and none is given here.
Habits over months. Fat loss, particularly visceral fat loss, is the most reliably reported lever. Regular aerobic and resistance training, improved sleep, reduced alcohol intake and stopping smoking are all associated with better metabolic profiles.
Life stage. Adiponectin levels differ by sex and age, which is why the reference table above is split by sex.
FitScript does not currently include adiponectin in its lab panels. Members who already have an adiponectin result from another laboratory can upload your existing labs so that Atlas, FitScript's AI health advisor, reads it alongside the rest of their biology rather than in isolation.
That context is the point. An adiponectin value of 11 µg/mL in a man with normal fasting insulin, normal A1C and a healthy waist measurement tells a different story than the same value alongside rising insulin and falling HDL. Atlas reads the marker against the other results on file and against the trend over time, and the interpretation it produces becomes part of your FitScript.
The membership covers 150+ biomarkers tested per year, and the broader metabolic picture those tests build is usually more actionable than any single hormone. Where a result pattern raises a question that a prescription option might address, a licensed provider evaluates the member and decides whether anything is appropriate. No treatment decision follows from a biomarker reading by itself.
This page is educational and is not medical advice. Review your own results, and any treatment you are considering, with a clinician or licensed provider who knows your history.
Adiponectin is most informative as part of a metabolic cluster, because each of the following markers captures a different part of the same system.
| Marker | What it adds next to adiponectin |
|---|---|
| Leptin | The counterpart hormone from fat tissue, which typically rises with fat mass. The adiponectin to leptin relationship is widely studied as a signal of fat tissue function. |
| Fasting Insulin | Shows how much insulin the pancreas is producing to keep glucose normal, often the earliest sign of reduced sensitivity. |
| HOMA-IR | Combines fasting glucose and insulin into a single index of insulin resistance, giving adiponectin a direct comparator. |
| HDL Cholesterol | Tends to move in the same direction as adiponectin, so the pair often rises or falls together. |
| Fasting Glucose | A snapshot of current glucose control, which usually shifts later than insulin or adiponectin. |
| Hemoglobin A1C | Reflects average glucose over the preceding months, anchoring the short-term markers in a longer trend. |
Read together, these six turn adiponectin from an interesting number into a usable one.
Adiponectin is a fat-derived hormone that supports insulin sensitivity and lowers inflammatory signalling, and it falls as visceral fat accumulates. Typical lab reference ranges are wide and differ by sex, so the trend over time matters more than one reading. Low values are associated with insulin resistance and the metabolic syndrome pattern; high values usually reflect leanness, but can also reflect kidney, cardiac or medication-related factors that deserve a clinician's attention. Nothing here diagnoses a condition, and no single marker should.
Most laboratories measure total adiponectin in the blood, reported in micrograms per millilitre. Some settings measure the high-molecular-weight fraction separately, which is generally regarded as the most metabolically active form. Because assays differ between laboratories and are not standardised, results from different labs are not directly comparable, so it is best to repeat testing at the same lab when tracking a trend.
No. In otherwise healthy, lean adults a higher value usually tracks with better insulin sensitivity. In older adults and in people with advanced kidney disease or heart failure, elevated adiponectin can sit alongside poorer outcomes, a pattern often called the adiponectin paradox. A markedly high result in someone who is not lean is worth discussing with a clinician promptly.
Typical lab reference ranges run roughly 4 to 40 µg/mL in men and 5 to 50 µg/mL in women, with women generally higher at the same body composition. FitScript's optimal ranges are 12 to 26 µg/mL for men and 18 to 37 µg/mL for women. Those optimal figures are optimization targets, not diagnostic cut-offs, and ranges vary by lab, age and sex.
A low result can point toward insulin resistance, but it does not establish it. Insulin resistance is assessed from a pattern, usually fasting insulin, fasting glucose, HOMA-IR and A1C, together with clinical context. A low adiponectin value is a reason to look at those markers with a clinician, not a diagnosis on its own.
Loss of visceral fat is the most consistently reported influence, and regular aerobic plus resistance training is associated with improved metabolic profiles. Changes are gradual, so retesting after a few weeks rarely shows anything meaningful.
Adiponectin is usually drawn fasting and in the morning, mainly for consistency across repeat tests rather than because eating dramatically changes the value. Follow whatever instructions the ordering laboratory or clinician gives, and keep the conditions the same each time so the comparison between draws stays valid.
Yes. Medicines affecting insulin sensitivity, hormones, inflammation or kidney function can shift it. Only a licensed provider who has reviewed your full medication list can judge what is contributing to a given result, and any treatment decision belongs with that provider.
FitScript does not currently include adiponectin in its lab panels. Members who already have a result from another laboratory can upload their existing labs so Atlas, FitScript's AI health advisor, reads it alongside their other biomarkers and the trend over time, rather than interpreting the single number in isolation.